GNS Stock Overview
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£49.94|
|52 Week High||UK£63.10|
|52 Week Low||UK£38.96|
|1 Month Change||-9.69%|
|3 Month Change||-15.86%|
|1 Year Change||20.05%|
|3 Year Change||110.01%|
|5 Year Change||175.76%|
|Change since IPO||3,599.26%|
Recent News & Updates
With EPS Growth And More, Genus (LON:GNS) Is Interesting
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Here's Why Genus (LON:GNS) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|GNS||GB Biotechs||GB Market|
Return vs Industry: GNS underperformed the UK Biotechs industry which returned 24.6% over the past year.
Return vs Market: GNS exceeded the UK Market which returned 11.6% over the past year.
|GNS Average Weekly Movement||4.7%|
|Biotechs Industry Average Movement||5.9%|
|Market Average Movement||4.9%|
|10% most volatile stocks in GB Market||9.7%|
|10% least volatile stocks in GB Market||2.5%|
Stable Share Price: GNS is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: GNS's weekly volatility (5%) has been stable over the past year.
About the Company
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand.
Genus Fundamentals Summary
|GNS fundamental statistics|
Is GNS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GNS income statement (TTM)|
|Cost of Revenue||UK£342.10m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.73|
|Net Profit Margin||8.24%|
How did GNS perform over the long term?See historical performance and comparison
0.6%Current Dividend Yield
Is Genus undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GNS (£49.94) is trading above our estimate of fair value (£28.25)
Significantly Below Fair Value: GNS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GNS is poor value based on its PE Ratio (68.6x) compared to the UK Biotechs industry average (63.1x).
PE vs Market: GNS is poor value based on its PE Ratio (68.6x) compared to the UK market (19.2x).
Price to Earnings Growth Ratio
PEG Ratio: GNS is poor value based on its PEG Ratio (5.1x)
Price to Book Ratio
PB vs Industry: GNS is overvalued based on its PB Ratio (6.5x) compared to the GB Biotechs industry average (6.3x).
How is Genus forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GNS's forecast earnings growth (13.3% per year) is above the savings rate (0.9%).
Earnings vs Market: GNS's earnings (13.3% per year) are forecast to grow faster than the UK market (12.3% per year).
High Growth Earnings: GNS's earnings are forecast to grow, but not significantly.
Revenue vs Market: GNS's revenue (6.7% per year) is forecast to grow faster than the UK market (4.9% per year).
High Growth Revenue: GNS's revenue (6.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GNS's Return on Equity is forecast to be low in 3 years time (12.3%).
How has Genus performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GNS has a large one-off loss of £14.1M impacting its June 30 2021 financial results.
Growing Profit Margin: GNS's current net profit margins (8.2%) are higher than last year (6.4%).
Past Earnings Growth Analysis
Earnings Trend: GNS's earnings have declined by 4.6% per year over the past 5 years.
Accelerating Growth: GNS's earnings growth over the past year (34%) exceeds its 5-year average (-4.6% per year).
Earnings vs Industry: GNS earnings growth over the past year (34%) underperformed the Biotechs industry 50.7%.
Return on Equity
High ROE: GNS's Return on Equity (9.4%) is considered low.
How is Genus's financial position?
Financial Position Analysis
Short Term Liabilities: GNS's short term assets (£231.7M) exceed its short term liabilities (£142.5M).
Long Term Liabilities: GNS's short term assets (£231.7M) exceed its long term liabilities (£211.9M).
Debt to Equity History and Analysis
Debt Level: GNS's net debt to equity ratio (15.6%) is considered satisfactory.
Reducing Debt: GNS's debt to equity ratio has reduced from 32.9% to 24.8% over the past 5 years.
Debt Coverage: GNS's debt is well covered by operating cash flow (54.7%).
Interest Coverage: GNS's interest payments on its debt are well covered by EBIT (13.1x coverage).
What is Genus's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GNS's dividend (0.6%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.38%).
High Dividend: GNS's dividend (0.6%) is low compared to the top 25% of dividend payers in the UK market (4.15%).
Stability and Growth of Payments
Stable Dividend: GNS is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.
Growing Dividend: GNS is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: GNS is not paying a notable dividend for the UK market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GNS's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stephen Wilson (61 yo)
Mr. Stephen Wilson serves as Chief Executive Officer and Executive Director of Genus plc since September 13, 2019. Mr. Wilson served as Group Finance Director of Genus plc since March 1, 2013 until Septemb...
CEO Compensation Analysis
Compensation vs Market: Stephen's total compensation ($USD3.84M) is above average for companies of similar size in the UK market ($USD1.75M).
Compensation vs Earnings: Stephen's compensation has increased by more than 20% in the past year.
Experienced Management: GNS's management team is considered experienced (4.5 years average tenure).
Experienced Board: GNS's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GNS insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Genus plc's employee growth, exchange listings and data sources
- Name: Genus plc
- Ticker: GNS
- Exchange: LSE
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£3.202b
- Shares outstanding: 64.95m
- Website: https://www.genusplc.com
Number of Employees
- Genus plc
- Matrix House
- Basing View
- RG21 4DZ
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/29 22:57|
|End of Day Share Price||2021/11/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.